What changed in this filing

/stocks — the workspaceLOADING

Item 3. Legal Proceedings

2022-02-18 compared with 2021-02-19 · 47 added, 20 removed, 79 unchanged (46% of the section changed)

LEGAL PROCEEDINGS

Abbott is involved in various claims, legal proceedings and investigations.

Abbott is involved in various claims, legal proceedings, and investigations, including (as of January 31, 2022) those described below.

While it is not feasible to predict the outcome of such pending claims, proceedings, and investigations with certainty, management is of the opinion that their ultimate resolution should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

Abbott is a defendant in numerous lawsuits involving certain of its specialty infant formula products administered to preterm infants.

The lawsuits allege that preterm infants developed necrotizing enterocolitis as a result of being administered a cow’s milk-based preterm infant formula product, which resulted in personal injuries or death.

As of January 31, 2022, there were 68 lawsuits pending in federal and state courts in which Abbott is a party.

The plaintiffs seek various damages, including punitive damages.

In January 2022, the U.S.

Judicial Panel on Multidistrict Litigation was asked to consolidate the federal court cases for pretrial purposes.

In addition, on December 15, 2021, a purported class of Canadian preterm infants filed suit in British Columbia making similar allegations against Abbott.

These plaintiffs seek various damages, including punitive damages.

Many of the lawsuits name another infant formula manufacturer as a co-defendant.

In June and July 2021, DexCom, Inc.

(DexCom) initiated patent infringement litigation against Abbott over certain of Abbott’s continuous glucose monitoring products, including those under the FreeStyle brand, in the U.S.

District Court for the Eastern District of Texas and in the Regional Court of Mannheim in Germany.

In both jurisdictions, DexCom seeks injunctive relief and monetary damages.

In all cases, Abbott asserts that it has a license to each of Dexcom’s asserted patents and that the patents are invalid and not infringed.

In July 2021, Abbott sued DexCom for patent infringement over certain of DexCom’s continuous glucose monitoring products in the U.S.

District Court for the District of Delaware, the Regional Courts of Mannheim and Dusseldorf in Germany, and the High Court of Justice in the United Kingdom.

Abbott seeks injunctive relief and monetary damages.

In December 2021, Abbott filed a breach of contract suit against DexCom in the U.S.

District Court for the District of Delaware alleging that DexCom breached the parties’ 2014 Settlement and License Agreement by asserting infringement of patents against Abbott that DexCom previously licensed to Abbott.

MINE SAFETY DISCLOSURES

9 unchanged sentences

There are no family relationships between any executive officers or directors.

2020 to present — Executive Chairman and Director.

1999 to 2020 — Chairman of the Board and Chief Executive Officer, and Director.

Elected Corporate Officer — 1993.

2020 to present — President and Chief Executive Officer, and Director.

2021 to present — Chairman of the Board and Chief Executive Officer, and Director.

2020 to 2021 — President and Chief Executive Officer, and Director.

2018 to 2020 — President and Chief Operating Officer, and Director since 2019.

17 unchanged sentences

Elected Corporate Officer — 2008.

2017 to present — Executive Vice President, Established Pharmaceuticals.

2015 to 2017 — Senior Vice President, Established Pharmaceuticals, Emerging Markets.

Joseph Manning, 53

2021 to present — Executive Vice President, Nutritional Products.

2017 to 2021 — Senior Vice President, International Nutrition.

2015 to 2017 — Vice President, Nutrition, Asia Pacific.

Elected Corporate Officer — 2015.

3 unchanged sentences

Daniel Salvadori, 43

2017 to present — Executive Vice President, Nutritional Products.

2021 to present — Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products.

2017 to 2021 — Executive Vice President, Nutritional Products.

2014 to 2017 — Senior Vice President, Established Pharmaceuticals, Latin America.

8 unchanged sentences

Elected Corporate Officer — 2017.

Christopher J.

2021 to present — Senior Vice President, U.S.

Elected Corporate Officer — 2015.

Brynelsen, 64

2017 to present — Senior Vice President, Abbott Vascular.

2016 to 2017 — Managing Director, CB Business Advisors, Inc.

(a medical device consulting firm).

2015 to 2016 — Senior Vice President and President, Medtronic Early Technologies, Medtronic plc (a global medical device company).

2017 to 2021 — Vice President, Pediatric Nutrition.

2014 to 2017 — Divisional Vice President and General Manager, Pediatric Nutrition.

Elected Corporate Officer — 2017.

9 unchanged sentences

Elected Corporate Officer — 2019.

Joseph Manning, 52

Fernando Mateus, 47

2021 to present — Senior Vice President, International Nutrition.

2015 to 2017 — Vice President, Nutrition, Asia Pacific.

2018 to 2021 — Divisional Vice President, EURISA, Abbott International Nutrition.

2016 to 2018 — Chief Executive Officer, Exeltis USA, Inc.

(a subsidiary of Exeltis, a women’s health company focused on respiratory, dermatology, and endocrinology).

Elected Corporate Officer — 2021.

2019 to present — Senior Vice President, Electrophysiology and Heart Failure.

2021 to present — Senior Vice President, Rapid Diagnostics.

2017 to 2021 — Vice President, Transfusion Medicine.

2015 to 2017 — Divisional Vice President and General Manager, Transfusion Medicine, ADD.

Elected Corporate Officer — 2017.

2021 to present — Senior Vice President, Electrophysiology

2019 to 2021 — Senior Vice President, Electrophysiology and Heart Failure.

2017 to 2019 — Senior Vice President, Cardiac Arrhythmias and Heart Failure.

1 unchanged sentence

Elected Corporate Officer — 2017.

Christopher J.

2019 to present — Senior Vice President, Rapid Diagnostics.

2015 to 2019 — Vice President, Diabetes Care, Commercial Operations.

2021 to present — Senior Vice President, Abbott Vascular.

April 2021 to July 2021 — Divisional Vice President, U.S.

Commercial, ADC.

2019 to 2021 — Divisional Vice President, Global Marketing, AVD.

2017 to 2019 — Divisional Vice President, U.S.

Sales and Marketing Endovascular, AVD.

Elected Corporate Officer — 2021.

14 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 3. Legal Proceedings